Nature Cell Biol:卵巢激素应答的乳腺干细胞与乳腺癌相关

2017-02-18 MEI 生物 360

Walter 和 Eliza Hall 研究所的研究人员使用先进的细胞、生物信息学和成像技术来揭示乳腺中长期存在的干细胞类型,其负责怀孕期间乳腺的生长。新发现的对“卵巢激素”孕酮和雌激素有反应的干细胞也可能与高风险形式的乳腺癌有关。

Walter 和 Eliza Hall 研究所的研究人员使用先进的细胞、生物信息学和成像技术来揭示乳腺中长期存在的干细胞类型,其负责怀孕期间乳腺的生长。新发现的对“卵巢激素”孕酮和雌激素有反应的干细胞也可能与高风险形式的乳腺癌有关。



这项发现是由 Nai Yang Fu 博士,Anne Rios 博士,Jane Visvader 教授和 Geoff Lindeman 教授作为一个为期 20 年的研究计划的一部分,该计划旨在揭示乳腺如何从干细胞发展,以及乳腺癌怎样从干细胞和乳腺组织中发生。 该研究于 2 月 13 日在 Nature Cell Biology 上发表 。

Fu 博士说,该团队已经能够通过定义具有不同功能的干细胞子集,在生物信息学研究员 Matthew Ritchie 博士和 Gordon Smyth 教授的合作下,在早期发现乳腺干细胞的基础上发展。

“当我们观察这些干细胞中接通的基因时,我们可以区分干细胞的子集,这些干细胞在编码两种称为 Tetraspanin8 和 Lgr5 的蛋白质的基因表达上不同,”他说。 “通过观察细胞表面上 Tetraspanin8 和 Lgr5 蛋白的水平,我们可以将干细胞分成三个独立的组。”

Rios 博士说,团队使用先进的技术,包括三维成像,显示三组干细胞位于乳房的不同部分,功能不同。

“我们特别关注一种具有最高水平的 Tetraspanin8 和 Lgr5 蛋白的干细胞亚型,其位于乳头周围乳房的近端区域。”Rios 博士说。

Visvader 教授说,这些干细胞通常是休眠 :静静地坐着而不分裂,并且在整个生命过程中待在近端区域。然而,当他们暴露于激素孕激素和雌激素时,这些细胞醒来,并可能迅速产生新的乳腺细胞。

研究还表明,具有高水平的 Tetraspanin8 和 Lgr5 蛋白的干细胞与被称为低密蛋白癌的“三阴性”乳腺癌亚型有许多相似之处。

“与其他类型的乳腺癌相比,低密蛋白癌在治疗后有很高的复发机会,导致患者的预后不良”Visvader 教授说。

Lindeman 教授,也是 Peter MacCallum 癌症中心和皇家墨尔本医院的医学肿瘤学家,他说这项研究可能会导致未来改善低密蛋白癌症患者的结局。“我们希望我们的发现可以用于了解癌症可能来自长寿的干细胞,并且可能导致乳腺癌患者的更好的结果。”

原始出处:

Nai Yang Fu,Anne C.Rios,et al. Identification of quiescent and spatially restricted mammary stem cells that are hormone responsive. Nature Cell Biology (2017) doi:10.1038/ncb3471

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881669, encodeId=b047188166927, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jun 22 06:35:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917373, encodeId=6fdd191e3739c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Nov 20 07:35:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767070, encodeId=3c361e670708c, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Mar 22 01:35:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869769, encodeId=03131869e69f0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 02 07:35:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960028, encodeId=88e51960028a9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 16 16:35:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
    2017-06-22 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1881669, encodeId=b047188166927, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jun 22 06:35:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917373, encodeId=6fdd191e3739c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Nov 20 07:35:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767070, encodeId=3c361e670708c, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Mar 22 01:35:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869769, encodeId=03131869e69f0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 02 07:35:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960028, encodeId=88e51960028a9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 16 16:35:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
    2017-11-20 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1881669, encodeId=b047188166927, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jun 22 06:35:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917373, encodeId=6fdd191e3739c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Nov 20 07:35:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767070, encodeId=3c361e670708c, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Mar 22 01:35:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869769, encodeId=03131869e69f0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 02 07:35:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960028, encodeId=88e51960028a9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 16 16:35:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1881669, encodeId=b047188166927, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jun 22 06:35:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917373, encodeId=6fdd191e3739c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Nov 20 07:35:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767070, encodeId=3c361e670708c, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Mar 22 01:35:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869769, encodeId=03131869e69f0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 02 07:35:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960028, encodeId=88e51960028a9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 16 16:35:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1881669, encodeId=b047188166927, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jun 22 06:35:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917373, encodeId=6fdd191e3739c, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Nov 20 07:35:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767070, encodeId=3c361e670708c, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Mar 22 01:35:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869769, encodeId=03131869e69f0, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 02 07:35:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960028, encodeId=88e51960028a9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 16 16:35:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
    2017-04-16 维他命

相关资讯

Circulation:乳腺癌放疗相关的心衰风险

心肌细胞可以耐受辐射。然而,心脏辐射暴露可以导致冠状动脉微血管内皮炎症,这种干扰涉及到心力衰竭(HF)的发病机理,特别是具有保留射血分数的HF(HFpEF)。乳腺癌的放射治疗导致不同的心脏辐射暴露,并可能增加HF的风险。近期,一项发表在Circulation杂志上的文章进行了一项有趣的研究。研究者们对利用计算机断层扫描辅助放射治疗计划进行乳腺癌放射治疗(1998-2013年)的170名明尼苏达州奥

盘点:乳腺癌治疗是否还是“雾里看花?

乳腺癌是发生在乳腺腺上皮组织的恶性肿瘤。全球乳腺癌发病率自20世纪70年代末开始一直呈上升趋势;我国乳腺癌的发病率也逐年上升,每年有近20万女性被诊断出乳腺癌。从死亡率的曲线也可以看出,随着新的治疗策略和方法的普及,虽然全球乳腺癌的死亡率逐步下降,但中国乳腺癌死亡率的下降趋势不显著。本文梅斯医学小编就1月份以来乳腺癌相关研究进行盘点,让我们一起看看,治疗乳腺癌是否还是“雾里看花”。【1】Cir

盘点:多篇文章阐明免疫系统与癌症发生的关联

我们都知道,当机体免疫系统发生故障时就有可能引发肿瘤产生;机体的免疫系统能够帮助我们攻击和消除病毒等其它外来异物以及癌细胞。在正常情况下,机体免疫系统随时都在监视和及时消灭这些异常细胞,当发现癌细胞后,T细胞首先主动出击,与癌细胞接触并牢牢地将其粘住,利用特殊酶类使癌细胞膜的通透性改变,促进癌细胞内部的钾离子大量流出,进而使得癌细胞失去渗透平衡,很快死亡。 机体会通过细胞免疫和体液免疫

中国乳腺癌患者生活方式指南

近30年来,随着临床诊疗水平的提高和乳腺癌筛查的普及,乳腺癌的生存率迅速提高,乳腺癌现患数量明显增多。我国女性乳腺癌患者的5年相对生存率估计为73.0%(71.2%~74.9%),在医疗条件较好的大城市可达80%。乳腺癌的总体生存状况明显好于其他常见恶性肿瘤,使得癌症生存者中乳腺癌患者比例较高;中国乳腺癌患者占全球乳腺癌患者的11.1%,占中国女性癌症患者的27.4%。

Clin&#160Cancer&#160Res:科学家定量化研究免疫细胞和个体乳腺癌风险之间的关联

图片摘自:newsletter.dole.com 2017年2月10日 讯 /生物谷BIOON/ --日前,一项刊登在国际杂志Clinical Cancer Research上的研究报告中,来自梅奥诊所的研究人员通过研究定量化地分析了多种类型免疫细胞的数量和个体患乳腺癌风险之间的关联。 研究者Amy Degnim博士表示,这项研究中我们首次分析了乳腺组织中多种类型免疫细胞的数量以及是否这

盘点:如何通过构建模型来助力人类疾病研究?

构建模型一直以来都是科学家们用以进行科学研究的关键方法,比如科学家们经常会构建疾病模型、动物模型、利用计算机开发出数学算法模型来用于人类疾病、药物开发等领域的研究,那么近年科学家利用模型进行研究取得了哪些突破性进展呢?本文中小编对此进行了整理,分享给各位! 【1】mBio  eLife:利用小型3D球体模型就能够有效抵御结核病 doi:10.7554/eLife.21283&